Bicycle Therapeutics (STU:50BA) Research & Development: €197.87 Mil (TTM As of Mar. 2026)


STU:50BA Bicycle Therapeutics PLC STU:50BA
54 GF Score
Price €3.48
GF Value €13.23
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bicycle Therapeutics Research & Development?

Bicycle Therapeutics STU:50BA +1.16% 54 Research & Development is €197.87 Mil as of Mar. 2026. GuruFocus rates STU:50BA with a GF Score™ of 54/100 and a GF Value™ of €13.23 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bicycle Therapeutics's Research & Development for the three months ended in Mar. 2026 was €42.30 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €197.87 Mil.

Bicycle Therapeutics  (STU:50BA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bicycle Therapeutics Research & Development Related Terms

Bicycle Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Bicycle Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicycle Therapeutics Research & Development Chart

Bicycle Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 39.72 77.04 143.51 165.18 205.20

Bicycle Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.63 61.58 49.78 44.21 42.30
STU:50BA
54GF Score
Bicycle Therapeutics PLC STU:50BA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicycle Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €197.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €197.87 Mil mean?
Bicycle Therapeutics (STU:50BA) has a Research & Development of €197.87 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Bicycle Therapeutics and its competitors.
Is Bicycle Therapeutics' Research & Development too high?
Bicycle Therapeutics' current Research & Development is €197.87 Mil. Overall, Bicycle Therapeutics has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' Research & Development compare to ABEO and DMAC?
Bicycle Therapeutics' Research & Development of €197.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bicycle Therapeutics and its competitors. Bicycle Therapeutics's current Research & Development is €197.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (STU:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €13.23, compared to a current price of €3.48 — trading 73.7% below its estimated fair value. The current Research & Development is €197.87 Mil. Bicycle Therapeutics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bicycle Therapeutics (STU:50BA), the current Research & Development is €197.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bicycle Therapeutics (STU:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.48 is trading 73.7% below its estimated GF Value™ of €13.23. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for STU:50BA:

  • Research & Development: €197.87 Mil
  • GF Value™: €13.23 vs. price of €3.48 (73.7% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the STU:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bicycle Therapeutics Business Description

Other Exchanges BCYC:USA
Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
54GF Score

Get the complete analysis for STU:50BA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.48
Price
€13.23
GF Value